Michelle Moorhouse, MB BCh, from Wits Reproductive Health and HIV Institute, works with the OPTIMIZE consortium, a group run by ICAP at Columbia University in New York City that seeks to simplify and make HIV treatments accessible.
The consortium’s ADVANCE trial is looking for a universal first-line HIV treatment regimen and was designed to examine three HIV drug combinations (Curr Opin HIV AIDS. 2017;12:351-354).
Speaking from the podium at the International AIDS Society (IAS) 2019 Conference on HIV Science, Moorhouse explained that “a real flurry” of reports started coming in about tenofovir alafenamide and dolutegravir being associated with weight gain.
Read the full article on Medscape